SQZ Pipeline
SQZ APCs: Oncology
COMMERCIALIZATION RIGHTS:
SQZ-PBMC-HPV
HPV+ Solid Tumors
SQZ-PBMC-X
Solid Tumors
Next Gen SQZ APC
Solid and Liquid Tumors
SQZ APCs: Infectious Disease
COMMERCIALIZATION RIGHTS:
SQZ-ID1
Chronic Infectious Disease
SQZ-RRV
Rapid Response Vaccines
SQZ AACs: Oncology
COMMERCIALIZATION RIGHTS:
SQZ-AAC-HPV
HPV+ Solid Tumors
SQZ-AAC-KRAS
KRAS mut Solid Tumors
Next Gen SQZ AAC
Solid and Liquid Tumors
SQZ TACs: Immune Tolerance
COMMERCIALIZATION RIGHTS:
SQZ-TAC-AAV
Gene Therapy Repeat Dosing
SQZ-TAC-T1D
Type 1 Diabetes
Next Gen SQZ TACs
Multiple Diseases
We and AskBio entered into a collaboration in 2019 to research the use of SQZ TACs to enable repeat dosing of gene therapies.
The JDRF T1D Fund has invested in SQZ Biotech on multiple occasions to help progress the T1D program.